Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment.

ABSTRACT:

Background

The aim of this study was to investigate the mechanism of the Poly ADP-ribose polymerase (PARP) inhibitor pamiparib (PAM) and the tyrosine kinase inhibitor anlotinib (ANL), utilizing a Biological Factor Regulatory Neural Network (BFReg-NN) and metabolomics approach.

Methods

Potential drug combinations were identified by integrating bioinformatics and machine learning algorithmic strategies. In vitro, their effects on ovarian cancer cells were detected by MTT assay, clone formation and annexin V/PI double staining, scratch assay and Transwell assay. The effect of PAM in combination with ANL was investigated in a nude mouse ovarian cancer model. The mechanism of action was investigated using an untargeted metabolomics approach. The inhibitory effect of the co

SUBMITTER: Wang D 

PROVIDER: S-EPMC12689557 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature